

Highlights of This Issue 5603

SPECIAL FEATURES

CCR Translations

- 5605 | **Heading in a New Direction:
Drug Permeability in
Breast Cancer Brain Metastasis**
George W. Sledge, Jr.
See article p. 5664

CCR New Strategies

- 5608 | **New Strategies in Peripheral T-Cell
Lymphoma: Understanding Tumor
Biology and Developing Novel
Therapies**
Kieron Dunleavy, Richard L. Piekarz,
Jasmine Zain, John E. Janik,
Wyndham H. Wilson, Owen A. O'Connor,
and Susan E. Bates

Molecular Pathways

- 5618 | **The Molecular Basis of
Lmo2-Induced T-Cell Acute
Lymphoblastic Leukemia**
David J. Curtis and Matthew P. McCormack
- 5624 | **Targeting Hypoxic Cells through
the DNA Damage Response**
Monica Olcina, Philip S. Lecane,
and Ester M. Hammond

HUMAN CANCER BIOLOGY

- 5630 | **Benign Mesenchymal
Stromal Cells in Human
Sarcomas**
Alexei Morozov, Robert J. Downey,
John Healey, Andre L. Moreira, Emil Lou,
Anna Franceschino, Yildirim Dogan,
Roland Leung, Mark Edgar,
Michael LaQuaglia, Robert G. Maki,
and Malcolm A.S. Moore

- 5641 | **Integrative Genomics Analyses
Reveal Molecularly Distinct
Subgroups of B-Cell Chronic
Lymphocytic Leukemia Patients with
13q14 Deletion**

Laura Mosca, Sonia Fabris, Marta Lionetti,
Katia Todoerti, Luca Agnelli,
Fortunato Morabito, Giovanna Cutrona,
Adrian Andronache, Serena Matis,
Francesco Ferrari, Massimo Gentile,
Mauro Spriano, Vincenzo Callea,
Gianluca Festini, Stefano Molica,
Giorgio Lambertenghi Delilieri,
Silvio Biccato, Manlio Ferrarini,
and Antonino Neri

- 5654 | **Foxo3a Suppression of Urothelial
Cancer Invasiveness through Twist1,
Y-Box-Binding Protein 1,
and E-Cadherin Regulation**

Masaki Shiota, YooHyun Song,
Akira Yokomizo, Keijiro Kiyoshima, Yasuhiro
Tada, Hiroshi Uchino,
Takeshi Uchiumi, Junichi Inokuchi, Yoshinao
Oda, Kentaro Kuroiwa,
Katsunori Tatsugami, and Seiji Naito

CANCER THERAPY: PRECLINICAL

- 5664 | **Heterogeneous Blood-Tumor
Barrier Permeability Determines
Drug Efficacy in Experimental Brain
Metastases of Breast Cancer**

Paul R. Lockman, Rajendar K. Mittapalli,
Kunal S. Taskar, Vinay Rudraraju,
Brunilde Gril, Kaci A. Bohn, Chris E. Adkins,
Amanda Roberts, Helen R. Thorsheim,
Julie A. Gaasch, Suyun Huang,
Diane Palmieri, Patricia S. Steeg,
and Quentin R. Smith
See commentary p. 5605

- 5679 | **Quercetin Induces Tumor-Selective
Apoptosis through Downregulation
of Mcl-1 and Activation of Bax**

Senping Cheng, Ning Gao, Zhuo Zhang,
Gang Chen, Amit Budhraj, Zunji Ke,
Young-ok Son, Xin Wang, Jia Luo,
and Xianglin Shi

- 5692 **Combination Therapy Targeting Both Tumor-Initiating and Differentiated Cell Populations in Prostate Carcinoma**
Anna Dubrovska, Jimmy Elliott, Richard J. Salamone, Sungeun Kim, Lindsey J. Aimone, John R. Walker, James Watson, Maira Sauveur-Michel, Carlos Garcia-Echeverria, Charles Y. Cho, Venkateshwar A. Reddy, and Peter G. Schultz
- 5703 **Highly Purified Eicosapentaenoic Acid as Free Fatty Acids Strongly Suppresses Polyps in Apc^{Min/+} Mice**
Lucia Fini, Giulia Piazzi, Claudio Ceccarelli, Yahya Daoud, Andrea Belluzzi, Alessandra Munarini, Giulia Graziani, Vincenzo Fogliano, Michael Selgrad, Melissa Garcia, Antonio Gasbarrini, Robert M. Genta, C. Richard Boland, and Luigi Ricciardiello
- 5712 **Noninvasive Radiofrequency Field Destruction of Pancreatic Adenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles**
Evan S. Glazer, Cihui Zhu, Katheryn L. Massey, C. Shea Thompson, Warna D. Kaluarachchi, Amir N. Hamir, and Steven A. Curley
- 5722 **Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses**
Ling-Yuan Kong, Adam S. Wu, Tiffany Doucette, Jun Wei, Waldemar Priebe, Gregory N. Fuller, Wei Qiao, Raymond Sawaya, Ganesh Rao, and Amy B. Heimberger
- 5734 **TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors**
Dominic Stadel, Andrea Mohr, Caroline Ref, Marion MacFarlane, Shaoxia Zhou, Robin Humphreys, Max Bachem, Gerry Cohen, Peter Möller, Ralf M. Zwacka, Klaus-Michael Debatin, and Simone Fulda
- 5750 **Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts**
Wei-meng Zhao, Lihong Wang, Hangil Park, Sophea Chhim, Melanie Tanphanich, Masakazu Yashiro, and K. Jin Kim
- 5759 **Effects of Siltuximab on the IL-6-Induced Signaling Pathway in Ovarian Cancer**
Yuqi Guo, Jeffrey Nemeth, Colin O'Brien, Michiro Susa, Xianzhe Liu, Zhan Zhang, Edwin Choy, Henry Mankin, Francis Hornicek, and Zhenfeng Duan
- 5770 **CEBPD Reverses RB/E2F1-Mediated Gene Repression and Participates in HMDB-Induced Apoptosis of Cancer Cells**
Yen-Chun Pan, Chien-Feng Li, Chiung-Yuan Ko, Min-Hsiung Pan, Pei-Jung Chen, Joseph T. Tseng, Wen-Chun Wu, Wen-Chang Chang, A-Mei Huang, Esta Sterneck, and Ju-Ming Wang
- 5781 **Dietary Curcumin Attenuates Glioma Growth in a Syngeneic Mouse Model by Inhibition of the JAK1,2/STAT3 Signaling Pathway**
Jakob Weissenberger, Maike Priester, Christian Bernreuther, Stefanie Rakel, Markus Glatzel, Volker Seifert, and Donat Kögel
- 5796 **DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer**
Brian M. Alexander, Kam Sprott, D. Allan Farrow, XiaoZhe Wang, Alan D. D'Andrea, Stuart J. Schnitt, Laura C. Collins, David T. Weaver, and Judy E. Garber
- 5805 **High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy**
Steven C.H. Kao, Nick Pavlakis, Rozelle Harvie, Janette L. Vardy, Michael J. Boyer, Nico van Zandwijk, and Stephen J. Clarke
- 5814 **Expression of Snail in Upper Urinary Tract Urothelial Carcinoma: Prognostic Significance and Implications for Tumor Invasion**
Takeo Kosaka, Eiji Kikuchi, Shuji Mikami, Akira Miyajima, Suguru Shirotake, Masaru Ishida, Yasunori Okada, and Mototsugu Oya

IMAGING, DIAGNOSIS, PROGNOSIS

5824 **Inflammatory and MicroRNA Gene Expression as Prognostic Classifier of Barrett's Associated Esophageal Adenocarcinoma**

Giang Huong Nguyen, Aaron J. Schetter, David B. Chou, Elise D. Bowman, Ronghua Zhao, Jason E. Hawkes, Ewy A. Mathe, Kensuke Kumamoto, Yiqiang Zhao, Anuradha Budhu, Nobutoshi Hagiwara, Xin Wei Wang, Masao Miyashita, Alan G. Casson, and Curtis C. Harris

5835 **Urine Metabolite Analysis Offers Potential Early Diagnosis of Ovarian and Breast Cancers**

Carolyn M. Slupsky, Helen Steed, Tiffany H. Wells, Kelly Dabbs, Alexandra Schepansky, Valerie Capstick, Wylam Faught, and Michael B. Sawyer

5842 **Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples**

Vera L. Costa, Rui Henrique, Stine A. Danielsen, Sara Duarte Pereira, Mette Eknaes, Rolf I. Skotheim, Ângelo Rodrigues, José S. Magalhães, Jorge Oliveira, Ragnhild A. Lothe, Manuel R. Teixeira, Carmen Jerónimo, and Guro E. Lind

CANCER THERAPY: CLINICAL

5852 **Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials**

Jeremy L. Davis, Marc R. Theoret, Zhili Zheng, Cor H.J. Lamers, Steven A. Rosenberg, and Richard A. Morgan

5862 **Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors**

Michele Del Vecchio, Roberta Mortarini, Stefania Canova, Lorenza Di Guardo, Nicola Pimpinelli, Mario R. Sertoli, Davide Bedognetti, Paola Queirolo, Paola Morosini, Tania Perrone, Emilio Bajetta, and Andrea Anichini

5873 **Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib**

Stephanie Heon, Beow Y. Yeap, Gregory J. Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, and Bruce E. Johnson

5883 **A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors**

Roy S. Herbst, Razelle Kurzrock, David S. Hong, Manuel Valdivieso, Cheng-Pang Hsu, Lovely Goyal, Gloria Juan, Yuying C. Hwang, Susan Wong, John S. Hill, Greg Friberg, and Patricia M. LoRusso

5892 **Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas**

Monica M. Mita, Matthew A. Spear, Lorrin K. Yee, Alain C. Mita, Elisabeth I. Heath, Kyriakos P. Papadopoulos, Kristine C. Federico, Steven D. Reich, Ofelia Romero, Lisa Malburg, MaryJo Pilat, G. Kenneth Lloyd, Saskia T.C. Neuteboom, Gillian Cropp, Edward Ashton, and Patricia M. LoRusso

5900 **Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer**

Ahmad Tarhini, Athanasios Kotsakis, William Gooding, Yongli Shuai, Daniel Petro, David Friedland, Chandra P. Belani, Sanja Dacic, and Athanassios Argiris

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

5908 **Decreased Expression of Cyr61 Is Associated with Prostate Cancer Recurrence after Surgical Treatment**


Katherine B. D'Antonio, Lucianna Schultz, Roula Albadine, Alison M. Mondul, Elizabeth A. Platz, George J. Netto, and Robert H. Getzenberg

CORRECTION

5914 **Correction: Systems-Level Analysis of Neuroblastoma Tumor-Initiating Cells Implicates AURKB as a Novel Drug Target for Neuroblastoma**

ABOUT THE COVER

Brain metastases of breast cancer are associated with significant morbidity and mortality. In their study, Lockman and colleagues quantified permeability, and paclitaxel and doxorubicin uptake in over 2000 experimental brain metastatic lesions from two model systems. The representative image shown on the cover is a multimodal image illustrating a single metastatic brain lesion which has 10 fold greater permeability compared to that of normal brain. Despite the increased permeability, drug accumulation only reached cytotoxic levels (>1000 ng/g) in a small subset of metastatic lesions, indicating that new brain-permeable drugs will be required. The picture was obtained by multichannel imaging of the eGFP MDA-MB-231Br lesion (green), indocyanine green within the vasculature (yellow), and ^{14}C -AIB phosphorescence (red). For further details, please see Lockman and coworkers on page 5664 in this issue.



Clinical Cancer Research

16 (23)

Clin Cancer Res 2010;16:5603-5914.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/16/23>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/16/23>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.